| Original language | English (US) |
|---|---|
| Article number | e205671 |
| Pages (from-to) | 50-51 |
| Number of pages | 2 |
| Journal | JAMA Oncology |
| Volume | 7 |
| Issue number | 1 |
| DOIs |
|
| State | Published - Jan 2021 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia : Updates from the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse. / Braun, Theodore P.; Druker, Brian J.
In: JAMA Oncology, Vol. 7, No. 1, e205671, 01.2021, p. 50-51.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
T2 - Updates from the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse
AU - Braun, Theodore P.
AU - Druker, Brian J.
N1 - Funding Information: receiving funding from the Howard Hughes Medical Institute; grants from the National Cancer Institute; personal fees from Aileron Therapeutics, Therapy Architects, Amgen, Aptose Biosciences, Iterion Therapeutics, Blueprint Medicines, the Burroughs Wellcome Fund, Cepheid, GRAIL, Enliven Therapeutics, the Novartis CML molecular monitoring steering committee, the RUNX1 Research Program, VBL Therapeutics, Vincera Pharma, Vivid Biosciences, Celgene, Gilead Sciences, and ICON; and additional support from Enliven Therapeutics, Novartis, Bristol Myers Funding Information: Dr Druker reports receiving funding from the Howard Hughes Medical Institute; grants from the National Cancer Institute; personal fees from Aileron Therapeutics, Therapy Architects, Amgen, Aptose Biosciences, Iterion Therapeutics, Blueprint Medicines, the Burroughs Wellcome Fund, Cepheid, GRAIL, Enliven Therapeutics, the Novartis CML molecular monitoring steering committee, the RUNX1 Research Program, VBL Therapeutics, Vincera Pharma, Vivid Biosciences, Celgene, Gilead Sciences, and ICON; and additional support from Enliven Therapeutics, Novartis, Bristol Myers Squibb, and Pfizer; he also reports a patent with royalties paid from Novartis for a treatment for gastrointestinal stromal tumors. No other disclosures were reported.
PY - 2021/1
Y1 - 2021/1
UR - http://www.scopus.com/inward/record.url?scp=85096175127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096175127&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2020.5772
DO - 10.1001/jamaoncol.2020.5772
M3 - Comment/debate
C2 - 33180121
AN - SCOPUS:85096175127
VL - 7
SP - 50
EP - 51
JO - JAMA oncology
JF - JAMA oncology
SN - 2374-2437
IS - 1
M1 - e205671
ER -